Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hectorol Label Hectored by ISMP

This article was originally published in The Pink Sheet Daily

Executive Summary

Medical safety organization says FDA will "look into" labeling of Bone Care International's Hectorol, which includes a mu and trailing zero.

You may also be interested in...



Pre-Dialysis Kidney Disease Market Heats Up With Oral Zemplar NDA, Hectorol Launch

Bone Care International's launch of the first vitamin D compound approved for secondary hyperparathyroidism in pre-dialysis patients (Hectorol) coincides with Abbott's NDA filing for Zemplar capsules.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications

New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal

Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.

Topics

UsernamePublicRestriction

Register

PS061857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel